NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Major Upgrade for Citius Oncology: Lymphir Launch Anticipation

Citius upgraded to Buy ($6). Lymphir launches in Q4 at high prices ($300K). Sales should jump fast starting in 2026.

Major Upgrade for Citius Oncology: Lymphir Launch Anticipation
Credit: Citius Oncology
Already have an account? Sign in.
09/23/2025 · 8:42 AM
CTOR
/ Read more

Feed↓

"We Pivoted Too Far" – Planet Fitness Stock Drops After Cutting Outlook
05/07/2026 · 12:54 PM

"We Pivoted Too Far" – Planet Fitness Stock Drops After Cutting Outlook

Planet Fitness stock fell after weaker growth forecast despite good Q1 results; company shifts back to low-cost gym focus.

/ Subscriber only
Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy
05/07/2026 · 11:55 AM

Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy

Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.

/ Subscriber only
Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
05/07/2026 · 11:15 AM

Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics

Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe